Based on these disappointing results, belimumab does not play a role in the maintenance of remission in ANCA-associated vasculitis, but a sequential use of rituximab and belimumab may be used in patients with frequently relapsing disease to block a subsequent increase in BLyS/BAFF levels following B cell depletion with rituximab. Here, TNFSF13B is linked to anti-neutrophil cytoplasmic antibody-associated vasculitis.